Pregled bibliografske jedinice broj: 887736
The efficacy and safety of valsartan and combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension - the VICTORY trial
The efficacy and safety of valsartan and combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension - the VICTORY trial // Kardiologia Polska, 75 (2017), 1; 55-64 doi:10.5603/KP.a2016.0135 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 887736 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
The efficacy and safety of valsartan and combination of valsartan and hydrochlorothiazide in the treatment of patients with mild to moderate arterial hypertension - the VICTORY trial
Autori
Accetto, Rok ; Yevgenyevna Chazova, Irina ; Sirenko, Yuriy ; Vincelj, Josip ; Widimsky Jr, Jiri ; Barbič- Žagar, Breda
Izvornik
Kardiologia Polska (0022-9032) 75
(2017), 1;
55-64
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
arterial hypertension ; fixed-dose combination ; valsartan
Sažetak
The aim of the trial was to establish the efficacy and safety of Valsacor (valsartan) and Valsacombi(combination of valsartan and hydrochlorotiazide) in a wide variety of patients populations with midl to moderate arterial hypertension. We performed an international, multicentre, open-label, prospective trial. After one week of washout in previously treated patients, the patients were treated for 16 weeks according to the protocol. Naive patients entered the treatment period immediately. During the active treatment, four visits were planned for each patients to obtain the data for the primary and secondary efficacy endpoints analysis. The pricipal methods were blood pressure (BP) measurement, additionally in a subgroup of patients, assessment of erectile function. The initial dosage of valsartan 80 mg/day was titrated up to 320 mg/day to achieve the BP goal, with the addition of hydrochlorothiazide (HTZ) in a fixed- combination (FDC), if needed. Mean +/- standard deviation changes from baseline at week 16 were -26.6 +/- 10.4 mm Hg (systolic BP) and -14.8 +/- 7.6 mm Hg (diastolic BP). A total of 91% of the patients treated with either valsartan or valsartan FDC achieved the BP goal. Adverse reactions were experienced by 7.1% of the patients, with the most common being headache (1.9%), palpitation (1.6%), dizzines (1.6%) and fatigue (1.6%), during the whole trial. The results of the VICTORY trial show that valsartan and valsartan FDC effectively reduce the BP in patients with mild to moderate arterial hypertension and have a good tolerability profile.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Klinička bolnica "Dubrava",
Zdravstveno veleučilište, Zagreb,
Medicinski fakultet, Osijek,
Sveučilište J. J. Strossmayera u Osijeku
Profili:
Josip Vincelj
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
Uključenost u ostale bibliografske baze podataka::
- EMBASE (Excerpta Medica)
- MEDLINE
- Scopus
- Index Copernicus
- EBSCO
- Cros Ref